Trimetazidine is a drug used to prevent or treat angina attacks—which is a type of chest pain caused by reduced blood flow to the heart—and other heart-related conditions. It works by increasing blood flow to the heart and limits rapid spikes in blood pressure.
Trimetazidine: Brand name| kamila valieva| Heart drug
Brand name:
| Product | Company | Price (Rs.) |
|---|---|---|
| Metagard CR 35mg Tablet 10s | Ipca Labs | 110.50 |
| Trivedon MR Tablet 10s | CIPLA | 128.50 |
| Carvidon MR Tablet 10s | Micro Labs | 131.00 |
Trimetazidine is described as the first cytoprotective anti-ischemic agent . Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism, also known as fatty acid oxidation inhibitor.
Trimetazidine usually prescribed as a long-term treatment of angina pectoris, and in some countries for tinnitus and dizziness.
Kamila Valieva:
Trimetazidine inhibits beta-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. In an ischaemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the beta-oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.
By preserving energy metabolism in cells exposed to hypoxia or ischaemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst maintaining cellular homeostasis.
Heart Drug:
Trimetazidine is a drug for angina pectoris sold under many brand names. Trimetazidineis described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | completely absorbed at around 5 hours, steady state is reached by 60th hour |
| Protein binding | low (16%) |
| Metabolism | minimal |
| Elimination half-life | 7 to 12 hours |
| Excretion | mainly renal (unchanged), exposure is increased in renal impairment – on average by four-fold in subjects with severe renal impairment (CrCl <30 ml/min) |
Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.
